Immunocore Q3: KIMMTRAK Sales $102.2M, Net Loss Widens to $14.2M, TEBE-AM Data Slips to Q2 2027
IMCR is trading near its 52-week low of $27.5 (0.7% above the low).
Summary
Immunocore's Q3 KIMMTRAK sales slipped 1.4% to $102.2 million and the net loss widened to $14.2 million, while the pivotal TEBE-AM overall survival readout slipped from end-2026 to Q2 2027. Roughly $901 million of cash and securities funds operations for at least twelve months.
Key Events · Earnings and Guidance · IMCR
-
TEBE-AM Readout Pushed to Q2 2027
Target enrollment of 540 patients is complete, but topline overall survival data in previously treated advanced cutaneous melanoma is now expected in Q2 2027 versus the prior end-2026 expectation.
-
Q3 KIMMTRAK Sales Slip 1.4%
Net product sales were $102.2 million versus $103.7 million a year earlier, attributed to Q2 2026 wholesaler stocking and one extra US sales week in Q3 2025; underlying growth was about 10%.
-
Net Loss Widens to $14.2M
Q3 net loss was $14.2 million ($0.28 per share) versus $0.177 million ($0.00) a year earlier, on R&D of $74.7 million and SG&A of $40.5 million; nine-month revenue rose 9.9% to $324.8 million.
-
Liquidity of About $901M
Cash and cash equivalents of $512.2 million plus marketable securities of $389.1 million as of September 30, 2026; the company states this funds operations for at least twelve months from the filing date.
Analysis · IMCR · Life Sciences
The headline is the TEBE-AM delay: topline overall survival data in previously treated advanced cutaneous melanoma is now expected in Q2 2027 rather than by end-2026, pushing the single biggest value driver for the stock out by roughly two quarters. Against that, the commercial base is holding: Q3 KIMMTRAK sales of $102.2 million were down 1.4% year over year but up about 10% on an underlying basis once Q2 wholesaler stocking and an extra Q3 2025 sales week are stripped out, and nine-month revenue rose 9.9% to $324.8 million. The quarter's $14.2 million net loss ($0.28 per share) versus roughly breakeven a year earlier reflects a 5.9% step-up in R&D to $74.7 million as the PRAME and tebentafusp programs advance. Cash of $512.2 million plus $389.1 million of marketable securities gives roughly $901 million of liquidity and at least twelve months of runway, so the delay is a valuation problem, not a solvency one.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCR was trading at $27.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $27.50 to $40.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.